This artice is free to access.
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.
Wu, J., Zhang, M., & Liu, D. (2016, March 9). Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-016-0250-9